advanced soft tissue sarcoma
About
Soft tissue sarcomas are a group of malignant tumors originating from mesenchymal tissue, including liposarcomas, leiomyosarcoma, synovial sarcoma and other types. Advanced patients are not sensitive to chemotherapy and have a very poor prognosis. Core dilemmas: ① There are many types and treatment needs to be individualized;② They are generally insensitive to chemotherapy;③ The 5-year survival rate of advanced patients is less than 20%;④ Targeted therapy is only effective for specific types.
Features & Symptoms
- derived from mesenchymal tissue
- Various types and strong heterogeneity
- Insensitive to chemotherapy
- Late prognosis is very poor
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| Trabectedin | Alkylating agents extracted from ascidians are effective against liposarcomas and leiomyosarcoma. | FDA批准 | $150K - $400K/疗程 |
| Eribulin | Microtubule inhibitor, effective against liposarcomas. | FDA批准 | $100K - $300K/疗程 |
| Targeted therapy (pazopanib/arlotinib) | Multi-target tyrosine kinase inhibitor for second-line treatment of advanced soft tissue sarcomas. | FDA批准 | $80K - $200K/年 |
Prognosis
Late 5-year survival rate <20%
Additional Notes
Notes: Molecular pathology testing: Molecular pathology testing is recommended (such as MDM2 amplification, fusion gene, etc.), which can guide diagnosis and treatment; Multidisciplinary management: requires multidisciplinary collaboration between the departments of surgery, radiotherapy, oncology and pathology to formulate a treatment plan; Surgical evaluation: It should be evaluated whether R0 resection can be achieved. Preoperative chemoradiotherapy and chemotherapy can improve the resection rate; Lung metastasis monitoring: The most common metastasis site of soft tissue sarcoma is the lung, and chest CT monitoring should be performed regularly; New drug clinical trials: Advanced patients may consider clinical trials of new targeted drugs (such as NTRK inhibitors for NTRK fusion-positive sarcomas). Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Study phase: FDA approval. Prognosis: Late 5-year survival rate <20%.
Frequently Asked Questions
What is advanced soft tissue sarcoma?
Soft tissue sarcomas are a group of malignant tumors originating from mesenchymal tissue, including liposarcomas, leiomyosarcoma, synovial sarcoma and other types. Advanced patients are not sensitive to chemotherapy and have a very poor prognosis. Core dilemmas: ① There are many types and treatment needs to be individualized;② They are generally insensitive to chemotherapy;③ The 5-year survival rate of advanced patients is less than 20%;④ Targeted therapy is only effective for specific types.
What are the symptoms of advanced soft tissue sarcoma?
derived from mesenchymal tissue,Various types and strong heterogeneity,Insensitive to chemotherapy,Late prognosis is very poor
How is advanced soft tissue sarcoma treated?
Trabectedin: Alkylating agents extracted from ascidians are effective against liposarcomas and leiomyosarcoma.; Eribulin: Microtubule inhibitor, effective against liposarcomas.; Targeted therapy (pazopanib/arlotinib): Multi-target tyrosine kinase inhibitor for second-line treatment of advanced soft tissue sarcomas.
What is the prognosis for advanced soft tissue sarcoma?
Late 5-year survival rate <20%